GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03364868

Recruitment Status : Active, not recruiting

First Posted : December 7, 2017

Last Update Posted : September 25, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

Helmholtz Zentrum München

University Hospital Carl Gustav Carus

Kinderkrankenhaus auf der Bult

Skane University Hospital

Universitaire Ziekenhuizen KU Leuven

Medical University of Warsaw

University of Oxford, Clinical Vaccine Research and Immunisation Education

Information provided by (Responsible Party):

Technical University of Munich

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	June 2024
Estimated Study Completion Date :	June 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Jacobsen LM, Schatz DA. Insulin immunotherapy for pretype 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2021 Aug 1;28(4):390-396. doi: 10.1097/MED.0000000000000648.

Ziegler AG, Achenbach P, Berner R, Casteels K, Danne T, Gundert M, Hasford J, Hoffmann VS, Kordonouri O, Lange K, Elding Larsson H, Lundgren M, Snape MD, Szypowska A, Todd JA, Bonifacio E; GPPAD Study group. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open. 2019 Jun 28;9(6):e028578. doi: 10.1136/bmjopen-2018-028578.

To Top